Drug pricing myths and realities: Beth Roberts
Original article featured on STAT
Turing Pharmaceuticals CEO Martin Shkreli and his notorious $750 pill have brought new media attention and public outcry to the already contentious issue of drug pricing. But Beth Roberts, partner in the health group at Hogan Lovells, argues that while profiteering stories get the bulk of the attention, the issue of drug pricing is much more complex. Roberts shares her views on some of the most common misperceptions related to the crucial issue of drug pricing.
MYTH: It’s all about profit.
REALITY: “Drug manufacturers want to be part of the solution, and they’re always looking at ways they can offer value-based pricing to the marketplace,” says Roberts. “[But] the regulatory environment – and the many laws that affect pricing – can make that challenging.”